Indication

Alzheimer's Disease

Clinical and regulatory intelligence for Alzheimer's Disease with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 1
Assets: 3

Relevant assets

ACP-204 →

donanemab →

Neurology →

Relevant companies

ACADIA Pharmaceuticals Inc. →

Eli Lilly →

Roche →

Recent signals(4)

ClinicalJune 17, 2026

Launch of Alzheimer's Disease Neuroimaging Initiative 4 to Validate Biomarkers

The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) aims to validate biomarkers and improve clinical trial design for Alzheimer's disease.

ClinicalJune 17, 2026

ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis

ACADIA Pharmaceuticals is launching a master protocol for three independent studies evaluating ACP-204 in Alzheimer's Disease Psychosis.

RegulatoryJune 16, 2026

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Detection

Roche has received CE Mark approval for Elecsys® pTau217, the first blood test designed to detect Alzheimer's disease pathology.

RegulatoryJune 16, 2026

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis

Roche has received CE Mark approval for Elecsys® pTau217, the first blood test for Alzheimer's disease pathology, enabling faster diagnosis.

Upcoming catalysts(1)

Advisory Committee

Eli Lilly — Donanemab

AdCom outcome will signal FDA tolerance for amyloid-lowering therapies in broader populations.

July 8, 2026 · NDA/BLA

Therapeutic areas

Alzheimer's Disease →

Neurology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.